National Institutes of Health

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

Invizyne specializes in the design of enzymes and the development of cell-free enzymatic pathways that operate independently of living cells. This innovative approach addresses many challenges associated with traditional biomanufacturing methods, which often rely on cell-based systems. By utilizing its proprietary platform, SimplePath, Invizyne aims to transform natural and renewable resources into a variety of valuable chemicals, including pharmaceuticals, fuels, materials, and food additives. The SimplePath system is designed as a modular cascade, allowing for efficient multi-step enzymatic processes. This positions Invizyne as a promising alternative to conventional chemical production methods, such as chemical synthesis and natural extraction, thus redefining the landscape of biomanufacturing.

GreenMark Biomedical Inc. is a healthcare company focused on developing minimally invasive technologies utilizing biopolymer nanoparticles derived from natural starch. Founded in 2016 and based in East Lansing, Michigan, with a laboratory in Ann Arbor, the company aims to enhance diagnostic and treatment capabilities in dentistry and oncology. GreenMark offers a mouth rinse product that highlights cavities and early-stage lesions, allowing dentists to accurately assess dental issues using standard dental curing lamps. Additionally, the company is working on medical applications that target anti-cancer drug delivery, facilitating site-specific treatments. Through its innovative approach, GreenMark Biomedical seeks to provide effective health-based solutions that improve patient care.

SonoMotion Inc. is a medical device company focused on developing non-invasive solutions for kidney stone disease. Founded in 2012 and based in San Mateo, California, the company offers innovative products such as Break Wave, which safely fragments large kidney stones, and Stone Clear, which aids in clearing the resulting stone fragments within 15 minutes in an office setting, without the need for general anesthesia or X-ray radiation. SonoMotion is actively involved in advancing its technology, with a stone repositioning solution currently undergoing clinical trials and a second-generation stone-breaking technology in development. The company's mission is to provide effective and cost-efficient treatments for kidney stone patients.

Lucid Diagnostics is a commercial-stage, cancer-prevention medical diagnostics company. Lucid focuses on patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard Esophageal DNA Test is performed on samples collected in a brief noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, a diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

Comprised of Ronald Reagan UCLA Medical Center, UCLA Medical Center, Santa Monica; Resnick Neuropsychiatric Hospital at UCLA, Mattel Children's Hospital UCLA, and the UCLA Medical Group with its wide-reaching system of primary-care and specialty-care offices throughout the region, UCLA Health System is among the most comprehensive and advanced healthcare systems in the world.

Neuronoff, a medical device company, is focused on the development of the Injectrode™, a novel injectable metal electrode, which is deployed via a small needle for manufacturing the neuromodulation interface inside the body on a variety of anatomical targets.

IVOS Medical is an innovative medical device company focused on advancing airway management technology.

Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Rhealth is a biotechnology company that focuses on delivering advanced health management solutions through an AI-driven platform tailored for hospitals. It aims to enhance the accessibility of analytical and diagnostic information for both physicians and patients. By integrating portable diagnostic and monitoring technologies, Rhealth seeks to transform the way health information is accessed and utilized, ultimately enabling healthcare providers to deliver more timely and effective care.

The University of Louisville is a public research university that offers a wide range of undergraduate and graduate programs across various disciplines. It is particularly known for its contributions to health, engineering, and the humanities. The university actively engages with community partners to enhance its academic and research initiatives, thereby creating a significant impact on education, healthcare, and research industries. Additionally, the University of Louisville School of Dentistry serves as a specialized institute within the university, focusing on dental education and training.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Scripps Health is a private, nonprofit integrated health system based in San Diego, California, dedicated to delivering high-quality medical care to patients and their families. The organization operates top-ranked hospitals and offers a range of services, including preventive care and wellness screenings tailored to various life stages. Additionally, the Scripps Health Foundation supports these efforts through philanthropic initiatives, ensuring the sustainability of quality patient care in the San Diego area.

Elimu Informatics is a developer of cloud-based clinical decision support software designed for healthcare professionals. The company's expertise lies in clinical decision support, semantic normalization, and workflow integration. By focusing on these areas, Elimu Informatics aims to enhance the quality of care, improve patient experiences, and increase usability for healthcare providers. Their solutions allow healthcare professionals to access advanced tools and insights without the burden of additional development costs or lengthy implementation timelines.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in the development of noninvasive electrophysiology devices aimed at monitoring, controlling, and repairing peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions at an earlier stage, track the progression of symptoms over time, and select more precise treatments tailored to individual patients' needs. This innovative approach enhances the ability of healthcare providers to address nerve-related issues effectively.

BMI OrganBank specializes in the development of advanced medical devices and perfusion technology aimed at enhancing the preservation of organs and tissues for transplantation. By collaborating with academic institutions, the company seeks to expand the potential of organ transplantation and improve patient outcomes. Its focus includes innovative solutions that could significantly transform kidney transplantation and other organ preservation methods, ultimately benefiting thousands of patients in need of transplants. The company’s efforts also extend to developing technologies for organ preservation, such as lung ventilators and ex vivo tissue perfusion, which enable healthcare providers to deliver better medical care.

Sparian Biosciences is an early-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the central nervous system (CNS). The firm focuses on creating unique medicines that target the brain, utilizing cutting-edge scientific approaches and novel drug discovery techniques. In addition to its core mission, Sparian is also developing a new analgesic aimed at addressing both acute and chronic pain, further emphasizing its commitment to advancing treatments for CNS-related conditions.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

Mount Sinai Health System is an integrated healthcare system based in New York, providing exceptional medical care to local and global communities. Established in 2013 through the merger of Mount Sinai Medical Center and Continuum Health Partners, it encompasses the Icahn School of Medicine and operates seven hospital campuses throughout the New York metropolitan area. The system is recognized for its excellence in research, patient care, and education across various specialties. It features a vast network of over 7,000 primary and specialty care physicians, as well as more than 45 ambulatory practices and 12 minority-owned free-standing ambulatory surgery centers. Mount Sinai is committed to improving healthcare quality and accessibility, focusing on compassionate patient experiences and the development of strong relationships between staff and patients. Additionally, its venture capital arm, Mount Sinai Ventures, invests in healthcare startups, further enhancing its capacity to innovate and respond to the diverse health needs of the populations it serves.

Novel Microdevices, LLC is focused on developing handheld devices for molecular diagnostics, specifically through its product, NOVEL DX. This innovative device utilizes microfluidics technology to analyze raw biological samples directly at the point of care, providing results in just 30 minutes. By enabling healthcare professionals to achieve lab-quality results without the need for a traditional laboratory setting, the device addresses various sectors including clinical diagnostics, biodefense, food safety, forensics, drug discovery, animal care, and agriculture. Founded in 2014 by Andrea Pais, Novel Microdevices is headquartered in Baltimore, Maryland.

Brixton Biosciences is a clinical-stage life sciences company focused on developing innovative therapies for chronic and acute pain management. The company aims to address significant unmet needs in this area, which has traditionally relied on systemic medications. Its flagship product, Neural Ice™, is a drug-free injectable treatment designed to induce reversible inhibition of nerves, offering a non-addictive, locally targeted solution. This therapy provides patients with extended pain relief lasting from thirty to sixty days following a single injection, representing a significant advancement over current pain management methods.

Young Heart Valve is a Polymeric, Hyaluronan-Enhanced Transcatheter Aortic Valves which were developed by engineers with inspiration from nature. The future of heart valve intervention is being altered by Young Heart Valve. Animal tissue is no longer required thanks to Young Heart Valve. Hyaluronan is included into the leaflets of Young Heart Valve's RejuvenateTM TAVR device, forming a biomolecular interpenetrated network that has been shown to be resistant to calcification and thrombosis.

ATCC global biological materials resource and standards organization whose mission focuses on the acquisition, authentication, production, preservation, development, and distribution of standard reference microorganisms, cell lines, and other materials. While maintaining traditional collection materials, ATCC develops high-quality products, standards, and services to support scientific research and breakthroughs that improve the health of global populations.

Caretaker Medical, LLC specializes in developing and manufacturing wireless patient monitoring devices. Its flagship product, CareTaker, is a wearable system that allows for continuous monitoring of vital signs, including blood pressure, heart rate, respiration rate, and other hemodynamic parameters, using a simple finger cuff. The device features integrated multi-mode radios for secure data transmission over cellular networks or Bluetooth, enabling healthcare providers to easily monitor patients' vital signs via a tablet or connected nurse station. Founded in 2014 and headquartered in Charlottesville, Virginia, with additional offices in Surrey, UK, and Beijing, China, Caretaker Medical aims to enhance patient outcomes and streamline care delivery across various healthcare settings, from hospitals to post-discharge environments.

Pip Care is a healthcare company that specializes in enhancing the surgical journey through a personalized platform designed for health systems. The company collaborates with these systems to streamline the perioperative care process, supporting care teams and patients from pre-surgery preparation to post-operative recovery. Pip Care offers a dedicated app that empowers patients by providing certified health coaches who create individualized care plans, including daily tasks and tailored advice, helping them manage appointments and feel prepared for their surgeries. By focusing on the digitization and automation of perioperative workflows, Pip Care aims to improve surgical outcomes for patients while also enhancing the financial performance of healthcare providers.

Teal Health is dedicated to improving women's health by providing at-home cervical cancer screenings. The company has developed an FDA-approved device that allows women to perform these essential screenings in the comfort and privacy of their own homes. By simplifying the process, Teal Health aims to encourage timely screenings, which are crucial for early detection and treatment, ultimately striving to eradicate cervical cancer in the United States. The initiative is supported by a group of committed investors who share the vision of transforming women's health experiences.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

CardieX Limited is a global health technology company specializing in cardiovascular health management. Founded in 1994 and headquartered in Sydney, Australia, the company designs, manufactures, and markets medical devices aimed at measuring patient risk for hypertension, cardiovascular disease, and other vascular disorders. Its product offerings include devices that utilize patented SphygmoCor technology to assess arterial stiffness and central blood pressure waveforms. Additionally, CardieX develops the Arty platform, which provides physiological and health analytics for wearable devices. The company also offers TeleHealth Services, connecting patients with health coaches through digital and mobile tools. CardieX's solutions are provided to hospitals, clinics, research institutions, and pharmaceutical companies globally. The company has strategic partnerships, including a collaboration with Blumio Inc. for developing wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. CardieX was previously known as AtCor Medical Holdings Limited until its name change in June 2018.

The University of Michigan, one of the largest universities in the Midwest, offers a diverse array of academic programs that attract over 40,000 undergraduate, graduate, and professional students. Its renowned schools include the Stephen Ross School of Business, the College of Engineering, and prominent law and medical schools. The university also has a vibrant arts scene, highlighted by its Musical Theatre program and the annual Ann Arbor Film Festival, which draws filmmakers globally. In addition to its educational endeavors, the University of Michigan actively manages a significant endowment, investing in alternative assets such as private equity, real estate, and infrastructure to support its mission and enhance its resources. The institution consistently ranks highly in national assessments, reflecting its commitment to academic excellence and innovation.

Southern California University of Health Sciences has been a leader in educating students to be competent and caring integrative healthcare practitioners for over 100 years. SCU has a history of providing the highest levels of patient care and has gained a reputation for excellence in an evidenceinformed curriculum. SCU is the best place to prepare for a successful, significant, and rewarding career.

The Instituto Nacional de Salud Publica is an academic institution whose central commitment to Mexican society is to provide research results to relevant public health problems in order to prevent and control diseases, as well as to train health professionals who help promote healthy living conditions in the community's various groups. population.

Rosalind Franklin University of Medicine and Science, established in 1912, is a North Chicago, Illinois-based institution dedicated to educating future health science leaders. It comprises five schools offering degrees such as Doctor of Medicine, Doctor of Podiatric Medicine, Nurse Anesthesia, Physical Therapy, and Physician's Assistant. The university fosters research and provides opportunities for students to engage in it, both on campus and through partnerships with nearby institutions. It aims to enrich students' lives professionally, mentally, and socially through various organizations and activities. Admission requirements vary by school but generally seek students with a strong scientific background and leadership skills. The university offers financial aid to eligible students who demonstrate need.

The Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute dedicated to understanding and treating various devastating illnesses, including Alzheimer's, heart disease, lupus, multiple sclerosis, and cancer. It operates a research facility, providing services and access to resources that facilitate drug discoveries and improve patient care.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Resvita Bio is engaged in the development and manufacturing of engineered probiotics aimed at treating skin-related diseases, including chronic conditions and cancer. The company focuses on creating a versatile skin microbial platform utilizing synthetic biology and metabolic engineering. This innovative approach allows for the continuous delivery of therapies that alleviate inflammation, promote tissue regeneration, and eliminate harmful bacteria. By leveraging this technology, Resvita Bio aims to offer faster and more efficient treatment alternatives for individuals suffering from chronic skin diseases.

Cenna Biosciences focuses on the discovery and development of innovative drugs aimed at preventing and treating Alzheimer's disease. The company utilizes a proprietary technology that targets the underlying cause of the disease, specifically addressing the harmful accumulation of beta-amyloid (Aß) in the brains of affected individuals. Cenna has identified a novel target and is in the process of developing several lead peptide compounds as potential disease-modifying treatments for Alzheimer's.

Lasarrus is a Baltimore-based company founded in 2013 that specializes in developing wearable devices for patients with chronic obstructive pulmonary disease (COPD). The company's innovative device is designed to enhance physical therapy by facilitating telemedicine and remote monitoring. It captures physiological and range-of-motion data, allowing patients to track their health routines effectively. Lasarrus aims to provide an affordable, comfortable, and non-invasive solution that accelerates recovery for users, improving their overall health management.

Tiziana Life Sciences is a clinical-stage biotechnology company based in London, UK, focused on discovering and developing novel therapeutic molecules for oncology and immunology. The company's product pipeline includes Foralumab, a human anti-CD3 monoclonal antibody aimed at treating autoimmune and inflammatory diseases such as graft-versus-host disease and multiple sclerosis. Another key asset is Milciclib, an orally bioavailable small molecule that inhibits cyclin-dependent kinases and is currently undergoing phase II clinical trials for epithelial thymic carcinoma. Additionally, Tiziana is developing Anti IL-6r, a monoclonal antibody targeting interleukin-6 for severe COVID-19 cases, and StemPrintER, a multi-gene signature assay for estrogen-receptor positive breast cancer patients. Founded in 2013, Tiziana Life Sciences is dedicated to advancing innovative therapies for serious diseases, including neurodegenerative disorders and lung diseases.

Nasoni, LLC specializes in the design and manufacture of fountain faucets, offering a range of products including centerset and widespread options in polished chrome, brushed nickel, and black nickel finishes. Established in 2015 and headquartered in Suffolk, Virginia, the company focuses on integrating advanced technology into its faucet solutions. Nasoni aims to transform bathrooms into centers of health and wellness, promoting personalized health experiences and enhancing daily self-care routines. The company sells its innovative products through sales representatives and online platforms, emphasizing the importance of maintaining health and wellness with greater independence and efficiency.

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of microRNA (miRNA) therapeutics to treat metastatic diseases. Founded in 2016, the company is dedicated to combating cancer through the targeted eradication of metastatic tumor cells, primarily leveraging its proprietary TTX nanoparticle platform. Its lead therapeutic candidate, TTX-MC138, aims to inhibit microRNA-10b, a key biomarker associated with metastasis, and has shown promising preclinical validation. Additionally, TransCode is advancing a portfolio of innovative RNA therapeutic candidates designed to address the challenges of RNA delivery, thereby expanding therapeutic options for various genetic targets within oncology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Evoq Therapeutics is a company specializing in cancer immunotherapy and the treatment of autoimmune diseases. It employs a proprietary technology platform that features a NanoDisc, designed to deliver disease-specific immune modulators effectively. This innovative approach aims to restore immune tolerance, allowing the body to better manage conditions such as celiac disease, type one diabetes, lupus, pemphigus, Graves' disease, and rheumatoid arthritis. By targeting these diseases through its novel nanodisc-based therapy, Evoq Therapeutics seeks to improve the lives of individuals affected by autoimmune disorders and enhance the overall efficacy of treatment strategies in various pre-clinical models.

Precision Epigenomics, established in 2020 and based in Tucson, Arizona, specializes in molecular diagnostics for cancer. The company focuses on developing innovative molecular diagnostic assays, leveraging DNA methylation analysis, an epigenetic modification, to enhance cancer diagnosis and treatment. Their offerings aim to address unmet clinical needs, aiding clinicians in improved patient management.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

Penderia Technologies is a medical device company focused on innovative orthopedic solutions. It develops implantable, battery-less sensors for monitoring injury and healing progress in real-time, enabling personalized rehabilitation therapies.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company based in Houston, Texas, that focuses on developing and commercializing T cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company’s MultiTAA technology enhances the effectiveness of non-engineered tumor-specific T cells, enabling them to target multiple tumor-associated antigens simultaneously. This approach aims to prevent immune escape and foster durable immunity. Marker Therapeutics offers autologous T cell therapies for conditions such as lymphoma and multiple myeloma, while also developing allogeneic T cell therapies for acute myeloid leukemia and acute lymphoblastic leukemia. Additionally, the company is advancing peptide-based vaccines, including TPIV100/110 and TPIV200, which are currently in Phase II clinical trials for treating breast and ovarian cancers, respectively.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Immunovia is a diagnostics company focused on the early detection of pancreatic cancer and other complex diseases. Utilizing its proprietary IMMray platform, which is based on antibody microarray analysis, Immunovia develops and commercializes innovative diagnostic tools. The company conducts clinical trials and validation studies to ensure the accuracy and reliability of its tests, collaborating with medical institutions and research centers worldwide. By concentrating on early detection, Immunovia aims to enhance the treatment and management of pancreatic cancer, thereby improving patient survival rates. The technology developed by Immunovia could also facilitate early detection strategies for other cancers and autoimmune diseases in the future.

Cortechs.ai is a developer of brain image analysis software that enhances clinical insight through quantitative imaging. The company's innovative solutions are utilized by neurologists and radiologists in numerous clinics and research centers globally. Its software provides a practical and cost-effective approach to quantifying brain structures, aiding medical professionals in the evaluation of various neurological conditions, including Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. Through its advanced imaging technology, Cortechs.ai aims to improve diagnostic accuracy and treatment outcomes in the field of neurology.

MaMome is dedicated to advancing women's health, beginning with pregnancy, and extending beyond, by utilizing microbiome coupled with machine learning/AI, we precisely identify expectant mothers at elevated risk of pregnancy complications.

Anebulo Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative treatments for individuals experiencing cannabinoid overdose and substance addiction. Its primary product candidate, ANEB-001, is designed to counteract the adverse effects of cannabinoid overdose within one hour of administration. Clinical trials have demonstrated that ANEB-001 is rapidly absorbed and well-tolerated by patients. Additionally, it has been observed to induce weight loss, an effect linked to its action as a central cannabinoid receptor type 1 antagonist. The company aims to address the wide range of symptoms associated with cannabinoid overdose, which can include profound sedation, anxiety, panic, and psychosis with hallucinations.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Weill Cornell Medicine operates as a leading medical and graduate school in New York City, focusing on excellence in patient care, scientific discovery, and the education of future physicians. The institution provides a comprehensive range of services, including medical consultancy, healthcare programs, and educational guidance, aimed at healthcare service providers, medical students, and governmental organizations. In addition to its educational mission, Weill Cornell Medicine includes specialized centers such as the Weill Cornell Vein Treatment Center, which offers treatments for various venous conditions and related health issues. The Information Technologies & Services Department plays a crucial role in supporting the institution’s objectives by delivering extensive IT infrastructure and services, enhancing research and clinical operations through innovative technology solutions. This multidisciplinary approach positions Weill Cornell Medicine as a leader in both medicine and technology.

VenoStent, Inc. is a clinical-stage tissue engineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Founded in 2017, it specializes in the development of bioresorbable smart polymers designed to enhance vascular surgery outcomes. The company’s primary product, SelfWrap, is a perivascular wrap that functions as an external stent, providing mechanical support to veins and promoting outward growth. This innovative technology aims to reduce complications at the vein-artery junction in dialysis patients, particularly by minimizing vein collapse and improving the usability of arteriovenous fistulas (AVF). By utilizing a new class of shape-memory polymers that do not require sutures, VenoStent's approach reduces surgery time and lowers the risk of infection, ultimately enhancing the quality and length of life for patients with chronic kidney disease undergoing hemodialysis.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

CUNY SPH promotes and sustains healthier populations in their city and around the world through education, research, and service in public health. They offer essential insights into public health problems and solutions. They believe collaboration leads to innovative and impactful research, programs, and policies.

Preeclampsia Foundation is a nonprofit that focuses on reducing maternal and infant illness and death due to preeclampsia.

Ensysce Biosciences is a clinical-stage biotechnology company focused on developing safer prescription drugs, particularly in the realm of opioid analgesics. Utilizing its proprietary technology platforms, specifically the Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR), Ensysce aims to create tamper-proof opioids designed to mitigate the risks of addiction and accidental overdose. These innovative drug formulations are intended to provide effective pain relief while reducing the human and economic toll associated with opioid misuse. The company is backed by a comprehensive intellectual property portfolio covering diverse prescription drug compositions, positioning it to make a significant impact on the opioid crisis.

Matter Bio is a biotechnology company dedicated to preserving genome integrity and enhancing longevity through the preservation of DNA information. The company aims to address the critical issue of information loss in the genome by assembling a team of expert scientists and executives. By focusing on mutation reversal, Matter Bio seeks to empower patients with the potential to improve their health and extend their lifespan. Through its innovative research services, the company strives to advance the understanding and application of genetic preservation techniques.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Phenomix Sciences is a biotechnology company founded in 2017 and headquartered in New York, United States. It specializes in the fields of metabolomics and genomics, focusing on developing healthcare solutions for personalized management of chronic diseases. The company has created a data analysis platform aimed at precision medicinal research for obesity management, which features a novel blood test and an AI-driven algorithm. This platform classifies the unique pathophysiological phenotype of patients with obesity, providing healthcare centers with tools and services that enhance the efficacy of obesity management while also reducing side effects and overall costs.

Arkansas Children's Research Institute is a not-for-profit organization affiliated with Arkansas Children's, Inc., and is dedicated to advancing pediatric health through research. It operates in conjunction with Arkansas Children's Hospital, the only pediatric medical center in Arkansas and one of the largest in the nation, which spans 29 city blocks and features 370 beds. The hospital employs around 500 physicians and more than 4,400 staff members, focusing on innovative medical research, surgical procedures, and intensive treatments aimed at improving children's health and development. The institute's research efforts contribute to the hospital's reputation for medical breakthroughs and have garnered recognition, including being ranked on the FORTUNE 100 Best Companies to Work For list for three consecutive years.

Annoviant is a healthcare company focused on the development of innovative medical devices, specifically tissue-based valve and conduit replacement products. These devices are designed to replace or repair structures that are congenitally absent or underdeveloped. Annoviant's offerings are characterized by their regenerative capabilities and resistance to thrombosis, calcification, and infection. By maintaining essential mechanical properties, these devices aim to enhance clinical outcomes for substitute conduit arteries in infants and children, ultimately reducing the need for repeated surgical interventions.

Selsym Biotech is a biotechnology company focused on developing innovative therapies aimed at controlling bleeding in trauma and surgical situations. The company's flagship product, Hemostatic Healing Hydrogels (H3), offers a novel solution to address critical challenges in hemorrhage control, particularly in light of ongoing platelet supply shortages and limitations related to shelf life. By providing effective platelet-mimetic therapies, Selsym Biotech seeks to revolutionize the management of uncontrolled bleeding, enhancing outcomes for patients in emergency and surgical settings.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

The University of California San Diego (UC San Diego) is a public research university renowned for its diverse undergraduate and graduate programs across multiple disciplines. It emphasizes research, community engagement, and interdisciplinary collaboration, making it a hub for innovation and education. The university houses the School of Medicine, which prepares students for careers in healthcare by equipping them with the necessary knowledge and skills to become dedicated medical professionals. Additionally, UC San Diego fosters a multidisciplinary approach to complex systems through its human-centered design thinking labs, collaborating with various industrial partners in fields such as automation and healthcare. It actively supports student involvement in leadership and offers resources for studying abroad, enhancing the overall educational experience.

The Feinstein Institutes is a research services centre.

Cincinnati Children’s Hospital Medical Center is a leading institution dedicated to improving child health, attracting patients and families both regionally and internationally. Recognized for its expertise, the hospital serves as a referral center for complex surgical procedures and treatments for rare pediatric diseases. The center is committed to advancing pediatric medicine by discovering innovative and effective treatment methods, solidifying its reputation as one of the foremost facilities for pediatric care globally.

Lamassu Pharma is a biotech startup dedicated to addressing the significant unmet medical need for severe acute pancreatitis. The company is focused on developing a novel small molecule therapy that has shown promising preclinical results in significantly reducing both mortality and morbidity associated with this condition. This therapeutic candidate, developed by leading scientists at Mayo Clinic, aims to improve medical outcomes for patients suffering from acute pancreatitis. Lamassu Pharma is currently advancing the development of this compound through safety testing, preparing for future clinical trials with the ultimate goal of saving lives and enhancing treatment options for those affected by this serious disease.

Springbok Analytics offers an AI-powered software platform that transforms MRIs into three-dimensional analyses of muscle to enable true precision. Springbok Analytics' advanced imaging technology identifies and measures each individual muscle, providing data to scientists, physical therapists, athletic trainers, and physicians to evaluate muscle function in relation to performance and injury management. The technology has numerous applications, including injury management, performance enhancement, and the treatment of musculoskeletal conditions.

Phase provides 3D-printing medical devices for microfluidics. Phase’s proprietary platform enables PDMS (Sylgard 184) to be 3D printed at a scale and resolution that was previously unattainable.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Perspective Therapeutics is a medical technology and radiopharmaceutical company focused on innovative cancer treatment solutions. The company employs a proprietary technology that uses the alpha-emitting isotope 212Pb combined with specialized targeting peptides to deliver targeted radiation directly to cancer cells. This approach aims to enhance the effectiveness of treatments while minimizing side effects, reflecting the company's commitment to personalized and precise medicine in addressing patients' medical needs.

BetterAge is a digital platform focused on enhancing the health and well-being of older adults. The company aims to empower individuals by providing hyper-personalized assistance that educates users about the risk levels of various diseases. This approach enables older adults to generate actionable insights and guidance, facilitating informed decision-making and connection to necessary resources. By leveraging a network of experts and practitioners in aging services, health, and technology, BetterAge is committed to creating supportive communities that foster active and healthy lifestyles for older individuals. The platform offers unique, expert-driven content tailored specifically for this demographic, promoting a vision where all adults can live well and age gracefully.

Maxim Biotech provides vitro diagnostic testing development and testing solutions.

AcuraStem Inc is a biotechnology company, founded in 2016 and based in Monrovia, California, that focuses on developing a precision medicine platform aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The company utilizes complex cellular models derived from ALS patients to evaluate disease progression and test existing FDA-approved therapeutics and their combinations. By employing advanced cellular reprogramming and artificial intelligence technologies, AcuraStem seeks to transform the standard of care for neurodegenerative diseases, enabling drug discovery companies to assess their therapeutic candidates more effectively. The team comprises experts, including PhDs, professors, and experienced professionals from the pharmaceutical industry, all dedicated to finding innovative treatments for this challenging health issue.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

InVivo Biosystems specializes in early biological and biomedical research by utilizing alternative, non-mammalian model organisms. The company develops and commercializes proprietary systems for the genetic modification of simple microscopic living animals, such as C. elegans and zebrafish, through its transgenic platform. These organisms serve as human proxies for disease research and drug discovery, helping researchers gain insights into genetic mutations and human health. InVivo Biosystems offers essential services to pharmaceutical, biotechnology, and academic institutions worldwide, aiming to accelerate their research and drug development efforts. The company's mission focuses on enhancing the understanding of high-impact disorders, including Alzheimer’s disease, epilepsy, and cancer, by providing an affordable and accessible research platform that facilitates mutant phenotyping, drug screening, and toxicological assessments.

RNAConnect specializes in developing enzymatic tools for visualizing and manipulating RNA, with a focus on low-abundance and long, structured RNAs. Their core product is a reverse transcriptase designed to provide greater visibility into these challenging RNA types and their various isoforms. This enzyme is optimized to synthesize cDNA with high fidelity and processivity, enabling researchers to study complex RNA template structures without the need for heat.

Midwest Bioprocessing Center is a pioneer in glycochemical bioprocess technology.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Orlance provides more effective therapeutic and preventive vaccines for a wide spectrum of viral targets.

Amydis is a privately-held pharmaceutical company focused on developing innovative diagnostic solutions for diseases associated with amyloid proteins. The company aims to create a universal, non-invasive diagnostic tool that is faster, more accessible, and affordable than existing tests for conditions with unmet clinical needs. Amydis has developed a platform of novel compounds that fluoresce upon binding to amyloid proteins, facilitating the diagnosis of various diseases. Its primary focus is on the early detection of Alzheimer's disease, but it also explores potential applications for detecting Parkinson’s disease, Creutzfeldt-Jakob disease, Pre-eclampsia, TTR Amyloidosis, and Cerebral Amyloid Angiopathy. By providing diagnostic capabilities for amyloid-associated diseases, Amydis empowers patients and healthcare professionals to make informed decisions about health risks.

Virtuoso Surgical focuses on developing robotic tools specifically for minimally invasive endoscopic surgery. The company's surgical system features needle-sized robotic arms that allow surgeons to navigate and operate in hard-to-reach areas of the body, addressing limitations posed by traditional endoscopes. By providing dexterous and accurate instruments, Virtuoso Surgical aims to enhance surgical precision and improve patient outcomes while also offering a cost-effective solution for healthcare providers.

The Stark Neurosciences Research Institute is dedicated to improving outcomes for persons suffering from disorders of the nervous system.

Hillhurst Biopharmaceuticals specializes in developing innovative, liquid therapeutic gases for treating sickle cell disease. Their core technology enables the precise, oral delivery of low-dose carbon monoxide, targeting a protective cellular mechanism to reduce inflammation, prevent cell death, and inhibit hemoglobin polymerization. This approach addresses challenges associated with traditional inhaled gas therapies, such as caregiver exposure and imprecise dosing, ensuring accurate and safe administration.

Endomimetics is focused on developing advanced bio-nanometric coating technology aimed at enhancing medical care for patients with kidney diseases. The company's innovative stent coating technology is designed to closely mimic human tissue, which helps to minimize the need for additional surgeries and improves the longevity of the devices. By reducing complications associated with the implantation of foreign materials, Endomimetics' technology aims to provide better outcomes for patients, ultimately improving their overall quality of care in the management of kidney-related health issues.

The New York Society for the Prevention of Cruelty to Children is a charity that offers counseling, legal, and educational services.

Center for HIV Identification, Prevention, and Treatment Services is a research organisation that conducts HIV research. They offers customer support through email and phone contact.

Rivanna Medical, LLC is a medical technology company based in Charlottesville, Virginia, founded in 2010. The company focuses on developing and commercializing innovative ultrasound-based systems aimed at enhancing the application of spinal and epidural anesthesia through advanced 3D navigation of the lumbar spine. Its flagship product, Accuro, not only facilitates precise anesthesia delivery but also supports various diagnostic imaging needs, including musculoskeletal and abdominal anatomies. Rivanna Medical is committed to improving patient outcomes and lowering healthcare costs while minimizing patient exposure to radiation commonly associated with X-ray-based imaging techniques.

L2P Research Labs is a preclinical contract research organization (CRO) that specializes in providing comprehensive research and development support. The company focuses on preclinical and toxicology services, utilizing proprietary orthotopic and metastatic tumor models. L2P Research Labs offers a range of advanced technologies, including quantitative whole-body animal imaging, small animal ultrasound, MRI, and CT scans, as well as focal radiation. These capabilities allow researchers to access a complete suite of research services tailored to their needs, facilitating the advancement of scientific studies and drug development.

RevBio is focused on developing innovative bone repair technology through its flagship product, Tetranite, which is an injectable, self-setting, osteoconductive bone adhesive biomaterial. This synthetic adhesive is designed to bond bone to bone and bone to metal in wet environments and is currently under FDA review for various applications in oral, craniofacial, orthopedic, and neurosurgical fields. Tetranite biodegrades over time, being replaced by new bone as part of the natural bone remodeling process, and serves as a scaffold to facilitate bone growth. By reducing the duration and complexity of medical procedures, RevBio's technology enables more minimally invasive surgeries and aims to improve patient outcomes by decreasing recovery time, pain, and overall costs associated with care. The company is building a diverse portfolio of applications within both dental and orthopedic markets.

BioCircuit Technologies, Inc. is a medical device company based in Atlanta, Georgia, founded in 2016. The company specializes in the development of noninvasive electrophysiology devices aimed at monitoring, controlling, and repairing peripheral nerves. By utilizing multi-electrode arrays and proprietary algorithms, BioCircuit's products enable clinicians to diagnose health conditions at an earlier stage, track the progression of symptoms over time, and select more precise treatments tailored to individual patients' needs. This innovative approach enhances the ability of healthcare providers to address nerve-related issues effectively.